ReviewAntioxidants (Basel, Switzerland)2024
Exploring the Therapeutic Potential of Natural Compounds in Psoriasis and Their Inclusion in Nanotechnological Systems.
Review in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Evaluation of the therapeutic potential of Iraqi Anagyris foetida L. leaf extracts in imiquimod-induced psoriasis-like skin lesions in mice.Protoplasma · 2026Article
- The Role of Phytocompounds and the Physiological Response of the Skin in Common Dermatological Conditions: A Narrative Review and Bibliometric Analysis of Trends.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Plant Extracts Downregulating the JAK/STAT Signaling Pathway as a Potential Tool for Psoriasis Management: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Interaction of Ferroptosis and Immune-Mediated Inflammation in Psoriasis.Antioxidants (Basel, Switzerland) · 2026Review
- Anti-Psoriatic activity ofOpen veterinary journal · 2026Article
- Celastrol protects against cisplatin-induced ovarian toxicity via modulation of PPAR-γ and AMPK.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Network pharmacology guided development and optimization of curcumin and sesame oil nanostructured lipid carriers for psoriasis.Scientific reports · 2025Article
- Jamamina: A Green Nanostructured Lipid Carrier with NaDES and Curcumin for Redox Modulation and Inflammatory Disorders.International journal of molecular sciences · 2025Article
- Recent advancement of fisetin-based nanoformulations in the management of psoriasis.Discover nano · 2025Review
- Targeting psoriatic inflammation with natural compounds: mechanistic insights and therapeutic promise.Inflammopharmacology · 2025Review
- Pharmaco-Toxicological Effects ofAntioxidants (Basel, Switzerland) · 2025Article
- Modulation of the KEAP1-NRF2 pathway by Erianin: A novel approach to reduce psoriasiform inflammation and inflammatory signaling.Open life sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory disease that affects around 2-3% of the world's population. The treatment for this autoimmune disease still remains centered around conventional methods using synthetic substances, even though more recent advancements focus on biological therapies. Given the numerous side effects of such treatments, current research involves plant extracts and constituents that could prove useful in treating psoriasis. The aim of this narrative review is to highlight the most known representatives belonging to classes of natural compounds such as polyphenols (e.g., astilbin, curcumin, hesperidin, luteolin, proanthocyanidins, and resveratrol), alkaloids (e.g., berberine, capsaicin, and colchicine), coumarins (psoralen and 8-methoxypsoralen), and terpenoids (e.g., celastrol, centelloids, and ursolic acid), along with plants used in traditional medicine that could present therapeutic potential in psoriasis. The paper also provides an overview of these compounds' mechanisms of action and current inclusion in clinical studies, as well as an investigation into their potential incorporation in various nanotechnological systems, such as lipid-based nanocarriers or polymeric nanomaterials, that may optimize their efficacy during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.